Showing 41-60 of 644 for: Cochrane Systematic Reviews > Psychiatric and substance abuse 
- Antidepressants for preventing postnatal depression
Cochrane Systematic Reviews, 18-Apr-2018
Depression is common in the postnatal period and can lead to adverse effects on the infant and wider family, in addition to the morbidity for the mother. It is not clear whether antidepressants are effective for the prevention of postnatal depression and
- Antidepressants for smoking cessation
Cochrane Systematic Reviews, 22-Apr-2020
Whilst the pharmacological profiles and mechanisms of antidepressants are varied, there are common reasons why they might help people to stop smoking tobacco. Firstly, nicotine withdrawal may produce depressive symptoms and antidepressants may relieve the
- Antidepressants for the negative symptoms of schizophrenia
Cochrane Systematic Reviews, 26-Apr-2012
Negative symptoms are common in people with schizophrenia and are often difficult to treat with antipsychotic drugs. Treatment often involves the use of various add-on medications such as antidepressants.
- Antidepressants for treating depression in adults with end‐stage kidney disease treated with dialysis
Cochrane Systematic Reviews, 23-May-2016
Depression affects approximately one-quarter of people treated with dialysis and is considered an important research uncertainty by patients and health professionals. Treatment for depression in dialysis patients may have different benefits and harms comp
- Antidepressants for treating depression in dementia
Cochrane Systematic Reviews, 31-Aug-2018
The use of antidepressants in dementia accompanied by depressive symptoms is widespread, but their clinical efficacy is uncertain. This review updates an earlier version, first published in 2002.
- Antidepressants plus benzodiazepines for adults with major depression
Cochrane Systematic Reviews, 3-Jun-2019
Anxiety frequently coexists with depression and adding benzodiazepines to antidepressant treatment is common practice to treat people with major depression. However, more evidence is needed to determine whether this combined treatment is more effective an
- Antidepressants versus placebo for depression in primary care
Cochrane Systematic Reviews, 8-Jul-2009
Concern has been expressed about the relevance of secondary care studies to primary care patients specifically about the effectiveness of antidepressant medication. There is a need to review the evidence of only those studies that have been conducted comp
- Antidepressants versus placebo for people with bulimia nervosa
Cochrane Systematic Reviews, 20-Oct-2003
Bulimia Nervosa (BN) represents an important public health problem and is related to serious morbidity and even mortality. This review attempted to systematically evaluate the use of antidepressant medications compared with placebo for the treatment of bu
- Antidepressants versus placebo for the depressed elderly
Cochrane Systematic Reviews, 22-Jan-2001
Depression warranting intervention is found in ten percent of people over the age of 60. Older depressed people are more likely to die than non-depressed. Relatively few receive therapeutic interventions, and those that do, tend to receive low dose antide
- Antidepressants versus psychological treatments and their combination for bulimia nervosa
Cochrane Systematic Reviews, 23-Oct-2001
Psychotherapeutic approaches, mainly cognitive behavior therapy, and antidepressant medication are the two treatment modalities that have received most support in controlled outcome studies of bulimia nervosa.
- Antiglucocorticoid treatments for mood disorders
Cochrane Systematic Reviews, 4-Dec-2015
Antiglucocorticoids may have antidepressant effects and have been reported to be efficacious in the treatment of severe psychiatric disorders. The efficacy and safety of antiglucocorticoid treatments for mood disorders is the subject of this systematic re
- Antipsychotic drug treatment for elderly people with late‐onset schizophrenia
Cochrane Systematic Reviews, 15-Feb-2012
Schizophrenia is usually considered an illness of young adulthood. However, onset after the age of 40 years is reported in 23% of patients hospitalised with schizophrenia. At least 0.1% of the world's elderly population have a diagnosis of late-onset schi
- Antipsychotic drugs for non-affective psychosis during pregnancy and postpartum
Cochrane Systematic Reviews, 20-Oct-2008
Antipsychotics are commonly prescribed for women suffering psychotic illnesses during pregnancy and the postpartum period. The potential adverse consequences of these different options are multiple and complex, impacting on the foetus, neonate, infant and
- Antipsychotic medication for challenging behaviour in people with learning disability
Cochrane Systematic Reviews, 11-Nov-2008
The term 'challenging behaviour', in the absence of psychiatric disorder, encompasses a wide range of behaviours that may be harmful to people or property, may be difficult to manage and may limit access to community facilities. Antipsychotic medications
- Antipsychotic medication for childhood‐onset schizophrenia
Cochrane Systematic Reviews, 18-Jul-2007
Childhood-onset schizophrenia is schizophrenia with onset prior to the age of 13 years. Although it is rare, people who suffer from schizophrenia at an early age appear to have a clinically severe form of the illness with poor long-term prognosis. Antipsy
- Antipsychotic medication for early episode schizophrenia
Cochrane Systematic Reviews, 16-Feb-2017
Long-term treatment with antipsychotic medications in early episode schizophrenia spectrum disorders is common, but both short and long-term effects on the illness are unclear. There have been numerous suggestions that people with early episodes of schizo
- Antipsychotic medication for elderly people with schizophrenia
Cochrane Systematic Reviews, 25-Jan-2006
A large and growing number of older people across the world suffer from schizophrenia. Recommendations for their treatment are largely based on data extrapolated from studies of the use of antipsychotic medications in younger populations. In addition most
- Antipsychotic medication versus placebo for people with both schizophrenia and learning disability
Cochrane Systematic Reviews, 17-Dec-2012
Antipsychotic medication is the standard treatment for people with learning disability and schizophrenia.
- Antipsychotic medications for cocaine dependence
Cochrane Systematic Reviews, 19-Mar-2016
Cocaine dependence is a public health problem characterised by recidivism and a host of medical and psychosocial complications. Cocaine dependence remains a disorder for which no pharmacological treatment of proven efficacy exists.
- Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia
Cochrane Systematic Reviews, 6-Feb-2018
Since the 1950s antipsychotic medication has been extensively used to treat people with chronic mental illnesses such as schizophrenia. These drugs, however, have also been associated with a wide range of adverse effects, including movement disorders such
